Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help
225 results
  1. Chronic Lymphocytic Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK66035
    ... in 175 patients.[ 10 ] Ibrutinib is a selective irreversible inhibitor of Bruton's tyrosine kinase, a signaling molecule ... obinutuzumab.[ 19 ] Acalabrutinib is a highly selective covalent irreversible Bruton tyrosine kinase inhibitor, designed to minimize the gastrointestinal toxicities and risk ...
  2. pdf45-56-1973.pdf 
    https://www.nlm.nih.gov/.../nlmarchives/techbull/45-56-1973.pdf
    ... ACID 2,4,5-TRICHLOROPHENOXYACETIC ACID CHOLINESTERASE INHIBITORS, IRREVERSIBLE CHOLINESTERASE INHIBITORS, REVERSIBLE ADRENERGIC ALPHA RECEPTOR BLOCKADERS ADRENERGIC BETA RECEPTOR ...
  3. NLM Digital Collections - Annual report - National Eye Institute (1993) 
    Publication: [Bethesda, Md.] : National Eye Institute
    resource.nlm.nih.gov/7802080X20
    ... T, Itabe H, Kador PF, Miller DD: Selective irreversible inhibitors of aldose reductase. J Med Chem 35:1117- ...
  4. NLM Digital Collections - Review of intramural research (1961) 
    Publication: [Bethesda, Md.] : U.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health
    resource.nlm.nih.gov/0141176X3
    ... chains would be more effective and per- haps irreversible inhibitors of the enzymes : -NH2 phenylethylamine (substrate) H E — ...
  5. NLM Digital Collections - Annual report - National Eye Institute (1994) 
    Publication: [Bethesda, Md.] : National Eye Institute
    resource.nlm.nih.gov/7802080X21
    ... 2 ceUs. (3) MDL 28,842, a potent irreversible inhibitor of S-adenosyl-L-homocysteine hydro- lase was shown ...
  6. NLM Digital Collections - Perioperative blood transfusion for elective surgery : a national clinical guideline 
    Publication: Edinburgh, Scotland : SIGN, 2001
    resource.nlm.nih.gov/101134791
    ... myocardial 1+ revascularisation.131,132 Aspirin is an irreversible inhibitor of cyclo-oxygenase, which platelets (unlike vascular endothelium) ...
  7. Breast Cancer Treatment (Adult) (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65744
    ... 6% vs. 0.2%). Neratinib Neratinib is an irreversible tyrosine kinase inhibitor of HER1, HER2, and HER4, which has been ...
  8. NLM Digital Collections - Symposium on Military Physiology : under the auspices of the Military Establishment Research .... 
    Publication: Washington, D.C. : Military Establishment Research and Development Board, Committee on Geographical Exploration, Panel on Physiology, [1947?]
    resource.nlm.nih.gov/06830900R
    ... new type of drugs to the pharmacological armamentarium - irreversible cholinesterase inhibitors lacking any independent pharmacological ac- tion. This is ...
  9. Introduction - Aspirin for the Primary Prevention of Cardiovascular Events - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK321625
    ... NSAIDs) and has been determined to be an irreversible cyclo-oxygenase (COX)-1 and -2 enzyme inhibitor, although unlike other NSAIDs, it affects more of ...
  10. NLM Digital Collections - Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia : effectiveness and value ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 22, 2017
    resource.nlm.nih.gov/101723938
    ... potentially important advancement for individuals with this frequently irreversible condition. In particular, for individuals with severe disabling TD, the use of VMAT2 inhibitors may decrease caregiver/family burden. ©Institute for Clinical ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last